Interleukin-1 Receptor Antagonist Haplotype Associated with Prostate Cancer Risk

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Aug 18

PMID 16106254

Citations 16

Authors

F Lindmark

S L Zheng

F Wiklund

K A Balter

J Sun

B Chang

M Hedelin

J Clark

J-E Johansson

D A Meyers

H-O Adami

W Isaacs

H Gronberg

J Xu

Affiliations

Soon will be listed here.

Abstract

IL1-RN is an important anti-inflammatory cytokine that modulate the inflammation response by binding to IL1 receptors, and as a consequence inhibits the action of proinflammatory cytokines IL1alpha and IL1beta. In this study, we hypothesise that sequence variants in the IL1-RN gene are associated with prostate cancer risk. The study population, a population-based case-control study in Sweden, consisted of 1383 prostate cancer case patients and 779 control subjects. We first selected 18 sequence variants covering the IL1-RN gene and genotyped these single-nucleotide polymorphisms (SNPs) in 96 control subjects. Gene-specific haplotypes of IL1-RN were constructed and four haplotype-tagging single-nucleotide polymorphisms (htSNPs) were identified (rs878972, rs315934, rs3087263 and rs315951) that could uniquely describe >95% of the haplotypes. All study subjects were genotyped for the four htSNPs. No significant difference in genotype frequencies between cases and controls were observed for any of the four SNPs based on a multiplicative genetic model. Overall there was no significant difference in haplotype frequencies between cases and controls; however, the prevalence of the most common haplotype (ATGC) was significantly higher among cases (38.7%) compared to controls (33.5%) (haplotype-specific P = 0.009). Evaluation of the prostate cancer risk associated with carrying the 'ATGC' haplotype revealed that homozygous carriers were at significantly increased risk (odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.2-2.2), compared to noncarriers, while no significant association was found among subjects heterozygous for the haplotype (OR = 1.0, 95% CI = 0.8-1.2). Restricting analyses to advanced prostate cancer strengthened the association between the 'ATGC' haplotype and disease risk (OR for homozygous carriers vs noncarriers 1.8, 95% CI = 1.3-2.5). In conclusion, the results from this study support the hypothesis that inflammation has a role of in the development of prostate cancer, but further studies are needed to identify the causal variants in this region and to elucidate the biological mechanism for this association.

Citing Articles

The Role of Interleukin-1-Receptor-Antagonist in Bladder Cancer Cell Migration and Invasion.

Schneider L, Liu J, Zhang C, Azoitei A, Meessen S, Zheng X Int J Mol Sci. 2021; 22(11).

PMID: 34070905 PMC: 8198563. DOI: 10.3390/ijms22115875.

Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.

Balazs K, Antal L, Safrany G, Lumniczky K J Pers Med. 2021; 11(4).

PMID: 33924671 PMC: 8070149. DOI: 10.3390/jpm11040296.

NFκB-Mediated Invasiveness in CD133 Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling.

Nomura A, Gupta V, Dauer P, Sharma N, Dudeja V, Merchant N Mol Cancer Res. 2017; 16(1):162-172.

PMID: 28970361 PMC: 5752573. DOI: 10.1158/1541-7786.MCR-17-0221.

Pro-Inflammatory Cytokine IL-1β Up-Regulates CXC Chemokine Receptor 4 via Notch and ERK Signaling Pathways in Tongue Squamous Cell Carcinoma.

Sun Y, Zhu D, Wang G, Wang D, Zhou H, Liu X PLoS One. 2015; 10(7):e0132677.

PMID: 26176534 PMC: 4503771. DOI: 10.1371/journal.pone.0132677.

IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status.

Worst T, Reiner V, Gabriel U, Weiss C, Erben P, Martini T Adv Urol. 2014; 2014:184602.

PMID: 25114677 PMC: 4119623. DOI: 10.1155/2014/184602.

References

Blakemore A, Cox A, Gonzalez A, Maskil J, Hughes M, Wilson R . Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet. 1996; 97(3):369-74. DOI: 10.1007/BF02185776. View

Lindmark F, Zheng S, Wiklund F, Bensen J, Balter K, Chang B . H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst. 2004; 96(16):1248-54. DOI: 10.1093/jnci/djh227. View

Machado J, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C . Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology. 2001; 121(4):823-9. DOI: 10.1053/gast.2001.28000. View

Shacter E, Weitzman S . Chronic inflammation and cancer. Oncology (Williston Park). 2002; 16(2):217-26, 229; discussion 230-2. View

Zheng S, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami H . Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res. 2004; 64(8):2918-22. DOI: 10.1158/0008-5472.can-03-3280. View

Clay F, Cork M, Tarlow J, Blakemore A, Harrington C, Lewis F . Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus. Hum Genet. 1994; 94(4):407-10. DOI: 10.1007/BF00201602. View

Sun J, Wiklund F, Zheng S, Chang B, Balter K, Li L . Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst. 2005; 97(7):525-32. DOI: 10.1093/jnci/dji070. View

Bootcov M, Bauskin A, Valenzuela S, Moore A, Bansal M, He X . MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997; 94(21):11514-9. PMC: 23523. DOI: 10.1073/pnas.94.21.11514. View

McCarron S, Edwards S, Evans P, Gibbs R, Dearnaley D, Dowe A . Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002; 62(12):3369-72. View

10.

Fallin D, Schork N . Accuracy of haplotype frequency estimation for biallelic loci, via the expectation-maximization algorithm for unphased diploid genotype data. Am J Hum Genet. 2000; 67(4):947-59. PMC: 1287896. DOI: 10.1086/303069. View

11.

Jonsson B, Bergh A, Stattin P, Emmanuelsson M, Gronberg H . Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer. 2002; 98(6):838-43. DOI: 10.1002/ijc.10258. View

12.

Schaid D, Rowland C, Tines D, Jacobson R, Poland G . Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002; 70(2):425-34. PMC: 384917. DOI: 10.1086/338688. View

13.

Steinkasserer A, Spurr N, Cox S, Jeggo P, Sim R . The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics. 1992; 13(3):654-7. DOI: 10.1016/0888-7543(92)90137-h. View

14.

Dinarello C . Biology of interleukin 1. FASEB J. 1988; 2(2):108-15. View

15.

McIntyre K, Stepan G, Kolinsky K, Benjamin W, Plocinski J, Kaffka K . Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med. 1991; 173(4):931-9. PMC: 2190808. DOI: 10.1084/jem.173.4.931. View

16.

El-Omar E, Carrington M, Chow W, McColl K, Bream J, Young H . Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000; 404(6776):398-402. DOI: 10.1038/35006081. View

17.

Bensen J, Langefeld C, Hawkins G, Green L, Mychaleckyj J, Brewer C . Nucleotide variation, haplotype structure, and association with end-stage renal disease of the human interleukin-1 gene cluster. Genomics. 2003; 82(2):194-217. DOI: 10.1016/s0888-7543(03)00123-x. View

18.

Cox A, Camp N, Nicklin M, Di Giovine F, Duff G . An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet. 1998; 62(5):1180-8. PMC: 1377075. DOI: 10.1086/301817. View

19.

De Marzo A, Marchi V, Epstein J, Nelson W . Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999; 155(6):1985-92. PMC: 1866955. DOI: 10.1016/S0002-9440(10)65517-4. View

20.

Witkin S, Gerber S, Ledger W . Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis. 2001; 34(2):204-9. DOI: 10.1086/338261. View